Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Clinical trial NCT02446093 · UNKNOWN
Trial details
- NCT number
- NCT02446093
- Sponsor
- Candel Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2025-12-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.